Eye on Industry, October 2008

Article

News from the ophthalmology industry, October 2008

Please click on any of the headlines below to see the full story.

B&L and Schwind join the femtosecond fan club
Bausch & Lomb and Schwind are following the latest industry trend by forming strategic alliances with femtosecond laser manufacturers 20/10 Perfect Vision and Ziemer Ophthalmic Systems, respectively. 

ICL and TICL counter LASIK slowdown
David Bailey, president of international operations at Staar Surgical, makers of the Visian ICL & TICL, says ICL technology allows surgeons to differentiate themselves in the slowing LASIK marketplace. Mr Bailey was speaking at a media briefing during this year's congress of the ESCRS in Berlin, Germany. 

Erratum
An article authored by Josef Reiter, MD, titled "My way to Epi-LASIK", which appeared in the July/August issue of Ophthalmology Times Europe, contained an error on page 20. 

 

For up-to-date news and announcements, please check the latest news section of our website. Alternatively, please sign up for our weekly newsletter.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Subscribe Now!
Recent Videos
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
At the American Society of Cataract and Refractive Surgeons annual meeting, Sheng Lim, MD, FRCOphth discusses the benefit of endoscopic cyclophotocoagulation for patients with primary open angle glaucoma and cataracts in the CONCEPT study
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
(Image credit: Ophthalmology Times Europe) AGS 2025: Clemens Strohmaier, PhD, on improving aqueous humour outflow following excimer laser trabeculostomy
3 experts are featured in this series.
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
3 experts are featured in this series.
Related Content
Topcon Healthcare, Inc. appoints Krysten Williams Head of Digital Solutions & Clinical Development – EMEA

Topcon Healthcare, Inc. appoints Krysten Williams Head of Digital Solutions & Clinical Development – EMEA

Sydney M Crago
May 9th 2025
Article

Williams joins Topcon Healthcare from Heidelberg Engineering, where she held multiple senior leadership roles.

PHOTON Results and Their Relation to DME Patients in Your Practice

PHOTON Results and Their Relation to DME Patients in Your Practice

July 25th 2024
Podcast

John Kitchens, MD, is joined by Diana Do, MD, to discuss the PHOTON trial results and their relation to patients with diabetic macular oedema in clinical practice.

Tepezza receives marketing authorisation from MHRA

Tepezza receives marketing authorisation from MHRA

Kassi Filkins
May 8th 2025
Article

Teprotumumab is the first therapy specifically licensed for the treatment of moderate-to-severe thyroid eye disease in the UK

PULSAR Results and Their Relation to nAMD Patients in Your Practice

PULSAR Results and Their Relation to nAMD Patients in Your Practice

July 24th 2024
Podcast

John Kitchens, MD, is joined by David Brown, MD, to discuss the PULSAR study results and their relation to patients with neovascular age-related macular degeneration in clinical practice.

Isarna Therapeutics shares positive results from Phase 2 BETTER trial

Isarna Therapeutics shares positive results from Phase 2 BETTER trial

Sydney M Crago
May 7th 2025
Article
OPGX-LCA5 gene therapy phase 1/2 data support potential to restore meaningful vision

OPGX-LCA5 gene therapy phase 1/2 data support potential to restore meaningful vision

Lynda Charters
May 6th 2025
Article

Opus Genetics reveals promising 1-year results from OPGx-LCA5 gene therapy, showing sustained vision improvements in adults with LCA5 retinal degeneration.

© 2025 MJH Life Sciences

All rights reserved.